主页 > 医学信息 >
【medical-news】肿瘤坏死因子抑制剂治疗银屑病性
http://www.medscape.com/viewarticle/561294
NEW YORK (Reuters Health) Aug 10 - Patients with psoriatic arthritis showed a greater disease response to treatment with antitumor necrosis factor (TNF) therapy than with conventional methotrexate treatment, Norwegian investigators report in the August issue of the Annals of the Rheumatic Diseases.
Dr. Marte Schrumpf Heiberg and colleagues at Diakonhjemmet Hospital in Oslo are conducting a longitudinal study of 526 patients with psoriatic arthritis, comparing the effects of TNF inhibitors, including infliximab, etanercept and adalimumab, with or without concomitant methotrexate with methotrexate alone.
The investigators measured disease activity and health-related quality of life at baseline and again at 3 and 6 months. Analyses of covariance (ANCOVA) were compared.
Patients reported on in this phase of study had been treated for at least 6 months.
The adjusted changes at 6 months were "significantly larger" in the anti-TNF group than in the methotrexate-treated patients for erythrocyte sedimentation rate and the disease activity score at 28 joints.
Improvements were also significant on the four-point medical health assessment questionnaire potassium depletion and in patients' assessments of pain, fatigue and global disease activity on a visual analogue scale and on the three-question short form.
"The introduction of biological drugs represents a major progress in the treatment of psoriatic arthritis, and has led to an increased interest in the disease," Dr. Heiberg and colleagues note.
"The efficacy of traditional disease-modifying anti-rheumatic drugs (DMARDs), by contrast, is poorly documented through systematic trials. Nevertheless, they are widely used, mainly based on the clinical impression that these drugs are effective," the researchers comment.
"Although no head-to-head comparisons have been performed between the different TNF-blocking agents, similar magnitude of clinical response has been observed across trials with the different agents with respect to joint symptoms, whereas improvements in skin manifestations seem to be somewhat greater with the monoclonal antibodies," the authors write.
"Our conclusion is that psoriatic arthritis patients seem to benefit more from TNF-blocking agents than methotrexate when treated in daily clinical practice. This result is consistent with findings in randomized clinical trials and contributes to improve external validity of results from randomized clinical trials examining anti-TNF drugs in psoriatic arthritis."
"However, more studies are needed to further establish the role of traditional DMARDs in the treatment of psoriatic arthritis," Dr. Heiberg and colleagues conclude.
Ann Rheum Dis 2007;66:1038-1042. 本人认领本文章，若48HR未能译出，请其他战友认领。 TNF Inhibitors Superior to Methotrexate for Psoriatic Arthritis
肿瘤坏死因子抑制剂治疗银屑病性关节炎优于甲氨喋呤
http://www.medscape.com/viewarticle/561294
NEW YORK (Reuters Health) Aug 10 - Patients with psoriatic arthritis showed a greater disease response to treatment with antitumor necrosis factor (TNF) therapy than with conventional methotrexate treatment, Norwegian investigators report in the August issue of the Annals of the Rheumatic Diseases.
纽约（路透社健康新闻）8月10日――－据挪威的科学家们在风湿病年会八月专题上报道，与常规使用甲氨蝶呤相比，肿瘤坏死因子拮抗剂治疗银屑病性关节炎的病人上显示出更好的疗效。
Dr. Marte Schrumpf Heiberg and colleagues at Diakonhjemmet Hospital in Oslo are conducting a longitudinal study of 526 patients with psoriatic arthritis, comparing the effects of TNF inhibitors, including infliximab, etanercept and adalimumab, with or without concomitant methotrexate with methotrexate alone.
在奥斯陆（挪威首都）的Diakonhjemmet 医院，Marte Schrumpf Heiberg医生与其同事正在进行一项涉及526个银屑病性关节炎病人的纵向研究，该项研究主要用于比较包括英夫利昔单抗，依那西普，adalimumab在内的肿瘤坏死因子拮抗剂联合使用甲氨蝶呤与单用甲氨蝶呤的2种方案之间的有何差别。
The investigators measured disease activity and health-related quality of life at baseline and again at 3 and 6 months. Analyses of covariance (ANCOVA) were compared.
研究者先衡量疾病的活动度以及健康相关的生活质量的基线值，于3个月，6个月再复测。方差分析也在比较之列。
Patients reported on in this phase of study had been treated for at least 6 months.
The adjusted changes at 6 months were "significantly larger" in the anti-TNF group than in the methotrexate-treated patients for erythrocyte sedimentation rate and the disease activity score at 28 joints.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-19 17:12
医学,生命科学网